Telesis Bio (TBIO) – StreetInsider.com Reports
-
Telesis Bio (TBIO) Announces CEO Change
-
Telesis Bio (TBIO) announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
-
Telesis Bio (TBIO) Report Prelim Q4
-
Transgenomic (TBIO) Misses Q3 EPS by 7c
-
Telesis Bio (TBIO) Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
-
Telesis Bio (TBIO) Announces Commercial Release of BioXp NGS Library Prep Kit for WGS
-
Telesis Bio (TBIO) Appoints William J. Kullback as CFO
-
Translate Bio (TBIO) PT Lowered to $4 at Jefferies
-
KeyBanc Downgrades Translate Bio (TBIO) to Sector Weight
-
Telesis Bio (TBIO) Announces 30.04M Share Offering by Selling Stockholders
-
Translate Bio (TBIO) Secures $28M in Financing
-
Transgenomic (TBIO) Tops Q1 EPS by 1c
-
Translate Bio (TBIO) Releases BioXp Select Kits
-
Transgenomic (TBIO) Tops Q4 EPS by 13c
-
Increasing unusual option volume: TBIO DOCN ALKS ARCT FIS ZI
-
Translate Bio (TBIO) PT Raised to $38 at SVB Leerink, Following Acquisition
-
Jefferies Downgrades Translate Bio (TBIO) to Hold Following Takeover
-
UPDATE: Correction: William Blair Downgrades Translate Bio (TBIO) to Market Perform, Following Acquisition
-
Increasing unusual option volume: TBIO SNCR ZI INFI ARCT YOU
-
Pre-Open Stock Movers 08/03: (OTLK) (TBIO) (HOLI) Higher; (CLX) (RNA) (KOPN) Lower (more...)
-
Sanofi (SNY) to Acquire mRNA Specialist Translate Bio (TBIO) for $3.2 Billion
-
Sanofi acquires Translate Bio (TBIO) for $38/sh, $3.2B Value
-
After-Hours Stock Movers 08/02: (TBIO) (PCSA) (SEDG) Higher; (RNA) (ADUS) (SANM) Lower (more...)
-
Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal
-
Sanofi (SNY) made an offer for Translate Bio (TBIO) - Reuters
-
Translate Bio (TBIO) Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
-
Translate Bio (TBIO) announces Brendan Smith appointed as Chief Financial Officer
-
Translate Bio (TBIO) Reports Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
-
SVB Leerink Downgrades Translate Bio (TBIO) to Market Perform
-
Translate Bio (TBIO) Appoints Dr. Rand Sutherland as President
-
Pre-Open Stock Movers 03/18: (UPST) (TKAT) (SINO) Higher; (TBIO) (CFRX) (RIDE) Lower (more...)
-
Translate Bio (TBIO) PT Lowered to $28 at H.C. Wainwright
-
Truist Securities Downgrades Translate Bio (TBIO) to Hold
-
After-Hours Stock Movers 03/17: (UPST) (WSM) (FIVE) Higher; (TBIO) (CFRX) (SLDB) Lower (more...)
-
Translate Bio (TBIO) Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
-
Sanofi (SNY) and Translate Bio (TBIO) Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
-
Translate Bio (TBIO) PT Raised to $31 at Goldman Sachs
-
Translate Bio (TBIO) Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
-
Translate Bio (TBIO) Announces Departure of CFO John Schroer
-
Translate Bio (TBIO) PT Raised to $37 at Roth Capital
-
Evercore ISI Resumes Translate Bio (TBIO) at Outperform
-
Translate Bio (TBIO) PT Raised to $21 at Goldman Sachs
-
Translate Bio (TBIO) PT Lowered to $18 at Goldman Sachs, Following Earnings
-
Sanofi (SNY) and Translate Bio (TBIO) mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
-
Goldman Sachs Starts Translate Bio (TBIO) at Buy
-
Translate Bio (TBIO) Resumes Enrollment and Dosing in Phase 1/2 Clinical Trial of MRT5005 in Cystic Fibrosis
-
Baupost's 13F Shows New Stakes in HCA (HCA), Verint Systems (VRNT), Increase in Atara (ATRA) and HD Supply (HDS) (More..)
-
Translate Bio (TBIO) PT Lowered to $25 at Jefferies
-
William Blair Starts Translate Bio (TBIO) at Outperform
-
French drugmaker Sanofi to cut up to 1,680 jobs in Europe
Back to TBIO Stock Lookup